Compare Dell Technologies Inc (DELL) vs Novavax Inc (NVAX) Price & Performance

Dell Technologies stock trades at $467.28, up 2.04% today, with strong bullish momentum driven by AI server demand and consistent earnings beats. The technical outlook is bullish with moving averages supporting upward trends, while fundamentals show revenue growth to $95.57B in 2025 and a net income margin of 6.28%. Analyst consensus is positive with a $503.76 price target, reflecting optimism around Dell's positioning in the AI infrastructure market.

The outlook for Dell remains favorable due to robust AI-driven server demand and solid financial performance, though risks include valuation concerns at a P/E of 35.14 and competitive pressures. Investors should weigh the growth potential against potential margin compression and market volatility.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.